Citations 96

ICU and Hospital Outcomes of Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation

A41. CRITICAL CARE: PREDICTING AND MEASURING OUTCOMES | July 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1628-A1628

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1628

Determinants of Health-Related Quality of Life as Assessed by the PAH-SYMPACT Questionnaire in Patients with Pulmonary Arterial Hypertension

B55. POT POURRI OF THE TOP CLINICAL STUDIES IN PULMONARY HYPERTENSION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A3799-A3799

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3799

Short and Long Termoxygenation Outcomes After Liver Transplantation for Hepatopulmonary Syndrome

B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2926-A2926

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2926

Health Disparities and Treatment Patterns in Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension: An Analysis of the Pulmonary Hypertension Association Registry

B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2906-A2906

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2906

Quality of Life as Assessed by the SYMPACT Questionnaire in Patients with Chronic Thromboembolic Pulmonary Hypertension

A54. WHAT'S NEW IN CTEPH?: CLINICAL STUDIES | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2046-A2046

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2046

A Case of Macrophage Activation Syndrome Associated with Parvovirus and Rheumatoid Arthritis

D52. CRITICAL CARE CASE REPORTS: RHEUMATOLOGY AND IMMUNOLOGY | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A7093-A7093

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7093

The Myths and Realities of Portopulmonary Hypertension

Hepatology | June 9, 2020 | Volume: 72 | Issue: 4 | Pages: 1455-1460

10.1002/hep.31415 | PMID 32515501

Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates

Liver Transplantation | May 12, 2020 | Volume: 26 | Issue: 8 | Pages: 989-999

10.1002/lt.25794 | PMID 32394590

We investigated the prevalence of spirometric restriction in liver transplantation (LT) candidates and the clinical impacts of restriction. We performed a cross‐sectional study within the Pulmonary Vascular Complications of Liver Disease 2 (PVCLD2) study, a multicenter prospective cohort study of patients being evaluated for LT. Patients with obstructive lung disease or missing spirometry or chest imaging were excluded. Patients with and without restriction, defined as a forced vital capacity (FVC) <70% predicted, were compared. Restriction prevalence was 18.4% (63/343). Higher Model for End‐Stage Liver Disease–sodium score (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02‐1.11; P = 0.007), the presence of pleural effusions (OR, 3.59; 95% CI, 1.96‐6.58; P < 0.001), and a history of ascites (OR, 2.59; 95% CI, 1.26‐5.33; P = 0.01) were associated with the presence of restriction, though one‐third with restriction had neither pleural effusions nor ascites. In multivariate analysis, restriction was significantly and independently associated with lower 6‐minute walk distances (least squares mean, 342.0 [95% CI, 316.6‐367.4] m versus 395.7 [95% CI, 381.2‐410.2] m; P < 0.001), dyspnea (OR, 2.69; 95% CI, 1.46‐4.95; P = 0.002), and lower physical component summary Short Form 36 scores indicating worse quality of life (least squares mean, 34.1 [95% CI, 31.5‐36.7] versus 38.2 [95% CI, 36.6‐39.7]; P = 0.004). Lower FVC percent predicted was associated with an increased risk of death (hazard ratio, 1.16; 95% CI, 1.04‐1.27 per 10‐point decrease in FVC percent predicted; P = 0.01). Restriction and abnormal lung function are common in LT candidates; can be present in the absence of an obvious cause, such as pleural effusions or ascites; and is associated with worse exercise capacity, quality of life, and survival.
Estrogen Metabolism in Portopulmonary Hypertension (POPH): A Case-Control Study

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5097-A5097

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5097

Awareness and Diagnostic Trends of Pulmonary Hypertension (PH) Amongst U.S.-Based Physicians

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5091-A5091

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5091